51 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28686445	39	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.	Sun Yat-Sen University
28406621	65	Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.	Dart Neuroscience
28165743	37	Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.	Dart Neuroscience
26978121	20	Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.	Sun Yat-Sen University
26935942	41	Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.	Mercachem
26562545	13	Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.	Institute of Radiopharmaceutical Cancer Research
25456383	113	Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.	TBA
25432025	34	Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.	Sun Yat-Sen University
24758746	36	Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.	Janssen Pharmaceutica
23260348	91	Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.	Janssen-Cilag
22985069	18	Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.	Sun Yat-Sen University
21988093	316	Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.	Pfizer
21955943	47	Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.	Pfizer
21983442	142	Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.	Biocrea
21087867	30	Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.	Universit£
20450197	80	Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.	Biotie Therapies
20196613	32	Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).	Pfizer
19631533	126	Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.	Pfizer
19339180	69	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.	Pfizer
32603117	32	Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.	Sun Yat-Sen University
27491708	31	Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.	Janssen Research & Development
32115956	46	Discovery and Optimization of ?-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.	Guangzhou University of Chinese Medicine
30916555	43	Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.	Sun Yat-Sen University
30888810	48	Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.	Sun Yat-Sen University
30148362	36	Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.	Sun Yat-Sen University
29291443	30	Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.	Sun Yat-Sen University
29718668	27	Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.	Pfizer
17507218	28	Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.	Abbott Laboratories
16603355	44	Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.	Abbott Laboratories
15261268	26	Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.	Aventis Pharma Deutschland
11591522	17	Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide.	Pfizer